Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts
Evommune, Inc. (NYSE:EVMN) has received a consensus recommendation of "Buy" from five analysts. The average 1-year target price is $39.33. Cantor Fitzgerald, Morgan Stanley, Evercore ISI, and Leerink Partners have all issued positive ratings, with target prices ranging from $36 to $42. Evommune is a clinical-stage biotechnology company focusing on therapies for chronic inflammatory diseases such as CSU, AD, and UC.
Evommune, Inc. (NYSE:EVMN - Get Free Report) has earned a consensus recommendation of "Buy" from the five ratings firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $39.3333.
Several research firms recently weighed in on EVMN. Cantor Fitzgerald began coverage on shares of Evommune in a research report on Monday. They issued an "overweight" rating for the company. Wall Street Zen raised Evommune to a "hold" rating in a research note on Thursday, November 20th. Morgan Stanley assumed coverage on Evommune in a research report on Monday. They set an "overweight" rating and a $36.00 target price for the company. Evercore ISI began coverage on Evommune in a research note on Monday. They set an "outperform" rating and a $40.00 price target on the stock. Finally, Leerink Partners began coverage on Evommune in a research report on Monday. They issued an "outperform" rating and a $42.00 price objective for the company.
Get Our Latest Analysis on Evommune
Evommune Stock Performance
EVMN opened at $20.71 on Monday. Evommune has a 1-year low of $16.70 and a 1-year high of $24.03.
About Evommune
(Get Free Report)Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions.
Featured Stories
- Five stocks we like better than Evommune
- What is a Secondary Public Offering? What Investors Need to Know
- Micron's $338 Target: The AI Memory Supercycle Is Just Starting
- Upcoming IPO Stock Lockup Period, Explained
- Bath & Body Works Hits Multi-Year Lows: Bargain or Trap?
- Retail Stocks Investing, Explained
- Worried About Inflation? These 3 ETFs Offer Real Protection
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Evommune Right Now?
Before you consider Evommune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evommune wasn't on the list.
While Evommune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
